Economic evaluation of healthcare interventions: old and new directions

Published on Jan 1, 2016in Oxford Review of Economic Policy
· DOI :10.1093/oxrep/grv020
Alastair Gray73
Estimated H-index: 73
Thomas Wilkinson1
Estimated H-index: 1
The techniques of economic evaluation have been increasingly widely applied in the health sector over recent decades, with hundreds of published evaluations performed in many countries and ranging across prevention programmes, diagnostics, treatment interventions, and the organization of health care. This paper examines the main methods in current use, and describes the gradual systematization of economic evaluation methodologies and the increasing importance of reimbursement agencies with explicit technical requirements. It reviews controversies in areas such as discounting, analytic perspective, identifying a cost-effectiveness threshold, differential treatment of particular disease areas or treatment groups, and the valuation of outcomes. It then considers in more detail the development of the World Health Organization’s generalized cost-effectiveness framework, and the emergence of an international ‘reference case’ commissioned by the Bill & Melinda Gates Foundation as a way of increasing the generalizability and comparability of such studies. Finally the paper discusses some current controversies and possible future developments in this field.
  • References (72)
  • Citations (8)
📖 Papers frequently viewed together
6 Citations
1 Author (Claudio Jommi)
1 Citations
3 Authors (Sarah Wordsworth, ..., Adrian Towse)
1 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Helen Dakin (University of Oxford)H-Index: 23
#2Nancy DevlinH-Index: 42
Last. David Parkin ('KCL': King's College London)H-Index: 32
view all 6 authors...
Background: The National Institute for Health and Care Excellence (NICE) emphasises that cost-effectiveness is not the only consideration in health technology appraisal and is increasingly explicit about other factors considered relevant. Observing NICE decisions and the evidence considered in each appraisal allows us to ‘reveal’ its implicit weights. Objectives: This study aims to investigate the influence of cost-effectiveness and other factors on NICE decisions and to investigate whether ...
100 CitationsSource
#1Benjarin Santatiwongchai (Health Intervention and Technology Assessment Program)H-Index: 3
#2Varit Chantarastapornchit (Health Intervention and Technology Assessment Program)H-Index: 3
Last. Yot Teerawattananon (Health Intervention and Technology Assessment Program)H-Index: 3
view all 8 authors...
Information generated from economic evaluation is increasingly being used to inform health resource allocation decisions globally, including in low- and middle- income countries. However, a crucial consideration for users of the information at a policy level, e.g. funding agencies, is whether the studies are comparable, provide sufficient detail to inform policy decision making, and incorporate inputs from data sources that are reliable and relevant to the context. This review was conducted to i...
18 CitationsSource
#1Scott D. Ramsey (UW: University of Washington)H-Index: 61
#2Richard J. Willke (Pfizer)H-Index: 26
Last. Sean D. Sullivan (UW: University of Washington)H-Index: 65
view all 8 authors...
Clinical trials evaluating medicines, medical devices, and procedures now commonly assess the economic value of these interventions. The growing number of prospective clinical/economic trials reflects both widespread interest in economic information for new technologies and the regulatory and reimbursement requirements of many countries that now consider evidence of economic value along with clinical efficacy. As decision makers increasingly demand evidence of economic value for health care inte...
172 CitationsSource
#1Mark Pennington (Lond: University of London)H-Index: 14
#2Richard Baker (GCU: Glasgow Caledonian University)H-Index: 54
Last. Cam Donaldson (GCU: Glasgow Caledonian University)H-Index: 60
view all 7 authors...
Background The appropriate thresholds for decisions on the cost‐effectiveness of medical interventions remain controversial, especially in ‘end‐of‐life’ situations. Evidence of the values placed on different types of health gain by the general public is limited. Across nine European countries, 17 657 people were presented with different hypothetical health scenarios each involving a gain of one quality adjusted life year (QALY) and asked about their willingness to pay (WTP) for that gain. The qu...
35 CitationsSource
#1Karl Claxton (Ebor: University of York)H-Index: 55
#2Stephen Martin (Ebor: University of York)H-Index: 21
Last. Mark Sculpher (Ebor: University of York)H-Index: 77
view all 9 authors...
A study by health economists at the University of York has, for the first time, produced an estimate of the impact on other NHS patients of new and more costly drugs and other treatments. This research suggests a refinement of the way the National Institute for Health and Clinical Excellence (NICE) gauges the cost-effectiveness of new interventions. It also has implications for the prices that the NHS can afford to pay for new drugs when the value-based pricing scheme for all new drugs is introd...
346 CitationsSource
#1Anthony J. CulyerH-Index: 41
7 Citations
#1W Kipviscusi (Vandy: Vanderbilt University)H-Index: 69
#2Joel Huber (Duke University)H-Index: 40
Last. Jason Bell (Duke University)H-Index: 10
view all 3 authors...
ABSTRACT This article estimates whether there is a cancer risk premium for the value of a statistical life using stated preference valuations of cancer risks for a large, nationally representative US sample. The present value of an expected cancer case that occurs after a one decade latency period is $10.85m, consistent with a cancer premium that is 21% greater than the median value of a statistical life estimates for acute fatalities. This cancer premium is smaller than the premium proposed for...
30 CitationsSource
#1Rachel Meacock (University of Manchester)H-Index: 9
#2Søren Rud Kristensen (University of Manchester)H-Index: 13
Last. Matt Sutton (University of Manchester)H-Index: 38
view all 3 authors...
Despite growing adoption of pay-for-performance (P4P) programmes in health care, there is remarkably little evidence on the cost-effectiveness of such schemes. We review the limited number of previous studies and critique the frameworks adopted and the narrow range of costs and outcomes considered, before proposing a new more comprehensive framework, which we apply to the first P4P scheme introduced for hospitals in England. We emphasise that evaluations of cost-effectiveness need to consider wh...
33 CitationsSource
#1David Canning (Harvard University)H-Index: 46
Cost-effectiveness analysis, which ranks projects by quality adjusted life years gained per dollar spent, is widely used in the evaluation of health interventions. We show that cost effectiveness analysis can be derived from two axioms: society prefers Pareto improvements and society values discounted life years, lived in perfect health, equally for each person. These axioms generate a unique social preference ordering, allowing us to find the cost effectiveness threshold to which health project...
5 CitationsSource
#1Warren G. Linley (Bangor University)H-Index: 3
#2Dyfrig A. Hughes (Bangor University)H-Index: 40
The criteria used by the National Institute for Health and Clinical Excellence (NICE) for accepting higher incremental cost-effectiveness ratios for some medicines over others, and the recent introduction of the Cancer Drugs Fund (CDF) in England, are assumed to reflect societal preferences for National Health Service resource allocation. Robust empirical evidence to this effect is lacking. To explore societal preferences for these and other criteria, including those proposed for rewarding new m...
115 CitationsSource
Cited By8
#1Anthony Kinghorn (University of the Witwatersrand)H-Index: 2
Sustaining HIV and AIDS responses depends on a mix of donor, government and private funders. Their decisions about investing in HIV treatment may be informed by various types of economic evaluation...
#1Vimbayi Mutyambizi-Mafunda (UCT: University of Cape Town)H-Index: 1
#2Bronwyn Myers (South African Medical Research Council)H-Index: 28
Last. Susan Cleary (UCT: University of Cape Town)H-Index: 20
view all 6 authors...
Introduction Depression and alcohol use disorders are international public health priorities for which there is a substantial treatment gap. Brief mental health interventions delivered by lay health workers in primary care services may reduce this gap. There is limited economic evidence assessing the cost-effectiveness of such interventions in low-income and middle-income countries. This paper describes the proposed economic evaluation of a health systems intervention testing the effectiveness, ...
#1Joanna Emerson (Tufts Medical Center)H-Index: 1
#2Ari D. Panzer (Tufts Medical Center)H-Index: 2
Last. David D. Kim (Tufts Medical Center)H-Index: 10
view all 10 authors...
Background The iDSI reference case, originally published in 2014, aims to improve the quality and comparability of cost-effectiveness analyses (CEA). This study assesses whether the development of the guideline is associated with an improvement in methodological and reporting practices for CEAs using disability-adjusted life-years (DALYs). Methods We analyzed the Tufts Medical Center Global Health CEA Registry to identify cost-per-DALY averted studies published from 2011 to 2017. Among each of 1...
1 CitationsSource
#1Sarah Paganini (University of Freiburg)H-Index: 5
#2Wiebke Teigelkötter (University of Freiburg)H-Index: 1
Last. Harald Baumeister (University of Ulm)H-Index: 33
view all 4 authors...
Abstract Background Internet- and mobile-based interventions (IMIs) targeting depression have been shown to be clinically effective and are considered a cost-effective complement to established interventions. The aim of this review was to provide an overview of the evidence for the cost-effectiveness of IMIs for the treatment and prevention of depression. Methods A systematic database search was conducted (Medline, PsychInfo, CENTRAL, PSYNDEX, OHE HEED). Relevant articles were selected according...
25 CitationsSource
#1Tom Drake (University of Oxford)H-Index: 10
#2Yoel Lubell (MU: Mahidol University)H-Index: 25
There is a growing evidence base on the cost effectiveness of malaria interventions. However, certain characteristics of malaria decision problems present a challenge to the application of healthcare economic evaluation methods. This paper identifies five such challenges. The complexities of (i) declining incidence and cost effectiveness in the context of an elimination campaign; (ii) international aid and its effect on resource constraints; and (iii) supranational priority setting, all affect h...
3 CitationsSource
Cost-effectiveness analysis (CEA) can help countries attain and sustain universal health coverage (UHC), as long as it is context-specific and considered within deliberative processes at the country level. Institutionalising robust deliberative processes requires significant time and resources, however, and countries often begin by demanding evidence (including local CEA evidence as well as evidence about local values), whilst striving to strengthen the governance structures and technical capaci...
8 CitationsSource
#1Nawaraj Bhattarai (Newcastle University)H-Index: 7
#2Peter McMeekin (Northumbria University)H-Index: 13
Last. Luke Vale (Newcastle University)H-Index: 50
view all 4 authors...
Objective To systematically review and appraise the quality of economic evaluations assessing centralisation of specialised healthcare services. Methods A systematic review to identify economic evaluations on centralisation of any specialised healthcare service. Full economic evaluations comparing costs and consequences of centralisation of any specialised healthcare service were eligible for inclusion. Methodological characteristics of included studies were appraised using checklists adapted fr...
13 CitationsSource
The international community, through the Millennium Development Goals and now the Sustainable Development Goals, has long recognized the critical role of improved global health in achieving social and economic development. This edition of the Oxford Review of Economic Policy explores whether this importance has been mirrored in the field of economics. It does so by bringing together the voices of 28 economists working on widely varying aspects of global health economics to confront three key pol...
4 CitationsSource